SV

Street Verdict

Analyst Scorecard

A record of what Amit Jain said publicly, with the source. Not advice.

“Bullish on the Pharmaceuticals sector, especially generics and API manufacturers, due to the exemption from Trump's latest tariff decision. This relief ensures continued momentum for the industry, with nearly 30% of India’s pharma exports going to the U.S.”
Nifty PharmaBullishCalled 04 Apr 2025
Verdict:PENDING

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Read the original articleSee Amit Jain’s full track record